Transcription factors remodel tumor immune microenvironment by impacting multiple immune cells Authors: Bei Xue, Chengwu He, Ye Tian Published: 2026 ABSTRACT Transcription factors (TFs) are key drivers of tumorigenesis because of their crucial role in regulating aberrant gene expression. They contribute to tumor cell proliferation, invasion, and migration and play a pivotal role in enabling tumors to evade immune detection. In the tumor immune microenvironment (TIME), TFs reprogram tumor-infiltrating immune cells to exert pro-tumor and anti-tumor effects. In this review, we have proposed a novel, mechanism-driven classification of TFs, categorizing them into direct-acting, trans-cellular coordinated, and dual-role TFs. We have investigated the roles of direct-acting TFs in regulating CD8+ T cell exhaustion, maintaining CD8+ T cell effector functions, influencing regulatory T cell infiltration and epigenetic modifications, modulating the polarization and infiltration of tumor-associated macrophages, and promoting pro-tumor or anti-tumor properties of natural killer cells, dendritic cells and Myeloid-derived suppressor cells. In addition, we have emphasized the trans-cellular coordinated TFs that serve as bridges, facilitating cooperation among different immune cells to remodel the TIME. Finally, we have highlighted dual-role TFs that exhibit opposing functions dictated by distinct isoforms, splice variants, or post-translational modifications. Additionally, we highlight emerging pharmacological strategies targeting TFs, emphasizing their clinical potential to reverse TIME immunosuppression and synergize with immune checkpoint inhibitors. With an enhanced understanding of the molecular mechanisms underlying tumorimmune system interactions within the TIME, next-generation therapeutic strategies targeting TFs can be developed. Introduction The tumor immune microenvironment (TIME) is a complex ecosystem comprising adaptive and innate immune cells that exhibit both pro-tumor and anti-tumor effects [1]. Heterogeneous infiltration of diverse immune cell types is a major external selection pressure that orchestrates tumor evolution [2]. The dynamic and continuous process of immune cell elimination from tumor cells remains an area of active research, with much remaining to be discovered regarding the diversity, plasticity, and functions of immune cells within the TIME [3]. Transcription factors (TFs) are DNA-binding proteins that have been identified as drivers of tumor progression, particularly by fostering an immunologically “cold” TIME, thereby disrupting immune-mediated tumor clearance [4–6]. The significance of TFs in the TIME has been underscored and validated by recent clinical studies that have demonstrated their efficacy in tumor immunotherapies which target TFs [7, 8]. To enhance the application of TFs as immunotherapy candidates, a comprehensive understanding of the mechanisms by which TFs remodel tumor-infiltrating immune cells is essential. To address the complex regulatory landscape of the TIME, we have proposed a novel, mechanism-driven classification of TFs in this review. TFs are traditionally categorized solely based on their resident immune cell types; however, we have delineated these regulators into three distinct operational groups: direct-acting TFs, which intrinsically dictate cell fate; trans-cellular coordinated TFs, which orchestrate immune-to-immune crosstalk; and dual-role TFs, whose divergent functions are governed by specific isoforms and post-translational modifications (Table 1). In addition to discussing current TF-targeted therapies, we propose that matching a specific TF to its corresponding functional category provides a basis for selecting the optimal therapeutic intervention, such as ex vivo cellular engineering, interception of intercellular signaling networks, or targeted biochemical modulation. Ultimately, we have aimed for this mechanistic framework to directly guide clinical decision-making and advance the design of precision immunotherapies. Table 1Transcription factors exhibit pro- or anti- tumor properties in reprogramming immune cellsFunctionRelative immune cellsTranscription factorsReferencesDirect-acting transcription factors Pro-tumorCD8+ T cellsNFAT5[18]IRF2[21]IKAROS[27]CD8+ T cells & TregBATF[27, 46, 48]TregSOX12[53]Treg & TAMSOX18[52]TAMSTAT6[65, 66]STAT3[70]NKELK3[86]EGR2[94]HIF-1α[87]MDSCsSTAT3[105]HIF-1α[112] Anti-tumorCD8+ T cellsIRF4[35, 36]TCF-1[27]BCL6[26]ETS1[27]TAMSOX17[74]DCSOX9[98]NF-κB[98]Trans-cellular coordinated transcription factors Pro-tumorNK & MDSCSTAT3[120]TAM & CD8+ T cellsIRF8[118] Anti-tumorTAM & CD8+ T cellsSTAT1[116]NK & CD8+ T cellsT-bet/Eomes[119]CD4+ & CD8+ T cellsBATF[121, 122]Dual-role transcription factors Pro- & Anti-tumorTregFOXP3[43, 44, 131]Treg & NKSTAT3[129, 132]TAM & NKZHX2[62, 82]TAM & DCTFEB[59, 100]DCC/EBPβ[102]NFAT: nuclear factor of activated T cell; IRF: Interferon regulatory factor; BATF: basic leucine zipper ATF-like transcription factor; SOX: sex-determining region Y (SRY)-related high-mobility group (HMG) box; STAT: signal transducer and activator of transcription; ELK3: ETS transcription factor ELK3; EGR2: early growth response 2; HIF-1α: hypoxia inducible factor 1 subunit alpha; TCF-1: T cell factor-1; BCL6: B cell lymphoma 6; ETS1: ETS proto-oncogene 1 ; NF-κB: nuclear factor kappa B; FOXP3: forkhead box protein 3; ZHX2: Zinc-fingers and homeoboxes 2; TFEB: Transcription factor EB; C/EBPβ: CCAAT/Enhancer binding proteins beta Table 1Transcription factors exhibit pro- or anti- tumor properties in reprogramming immune cellsFunctionRelative immune cellsTranscription factorsReferencesDirect-acting transcription factors Pro-tumorCD8+ T cellsNFAT5[18]IRF2[21]IKAROS[27]CD8+ T cells & TregBATF[27, 46, 48]TregSOX12[53]Treg & TAMSOX18[52]TAMSTAT6[65, 66]STAT3[70]NKELK3[86]EGR2[94]HIF-1α[87]MDSCsSTAT3[105]HIF-1α[112] Anti-tumorCD8+ T cellsIRF4[35, 36]TCF-1[27]BCL6[26]ETS1[27]TAMSOX17[74]DCSOX9[98]NF-κB[98]Trans-cellular coordinated transcription factors Pro-tumorNK & MDSCSTAT3[120]TAM & CD8+ T cellsIRF8[118] Anti-tumorTAM & CD8+ T cellsSTAT1[116]NK & CD8+ T cellsT-bet/Eomes[119]CD4+ & CD8+ T cellsBATF[121, 122]Dual-role transcription factors Pro- & Anti-tumorTregFOXP3[43, 44, 131]Treg & NKSTAT3[129, 132]TAM & NKZHX2[62, 82]TAM & DCTFEB[59, 100]DCC/EBPβ[102]NFAT: nuclear factor of activated T cell; IRF: Interferon regulatory factor; BATF: basic leucine zipper ATF-like transcription factor; SOX: sex-determining region Y (SRY)-related high-mobility group (HMG) box; STAT: signal transducer and activator of transcription; ELK3: ETS transcription factor ELK3; EGR2: early growth response 2; HIF-1α: hypoxia inducible factor 1 subunit alpha; TCF-1: T cell factor-1; BCL6: B cell lymphoma 6; ETS1: ETS proto-oncogene 1 ; NF-κB: nuclear factor kappa B; FOXP3: forkhead box protein 3; ZHX2: Zinc-fingers and homeoboxes 2; TFEB: Transcription factor EB; C/EBPβ: CCAAT/Enhancer binding proteins beta Transcription factors exhibit pro- or anti- tumor properties in reprogramming immune cells NFAT: nuclear factor of activated T cell; IRF: Interferon regulatory factor; BATF: basic leucine zipper ATF-like transcription factor; SOX: sex-determining region Y (SRY)-related high-mobility group (HMG) box; STAT: signal transducer and activator of transcription; ELK3: ETS transcription factor ELK3; EGR2: early growth response 2; HIF-1α: hypoxia inducible factor 1 subunit alpha; TCF-1: T cell factor-1; BCL6: B cell lymphoma 6; ETS1: ETS proto-oncogene 1 ; NF-κB: nuclear factor kappa B; FOXP3: forkhead box protein 3; ZHX2: Zinc-fingers and homeoboxes 2; TFEB: Transcription factor EB; C/EBPβ: CCAAT/Enhancer binding proteins beta Direct-acting transcription factors Direct-acting TFs are at the foundational level of transcriptional regulation within the TIME. These regulators effectively influence cell programming by binding directly to specific target gene promoters and enhancers (Table 1). To identify these TFs, we have categorized them based on the specific immune cell populations that they govern. Specifically, we have investigated their roles in regulating CD8+ T cell exhaustion, maintaining CD8+ T cell effector functions, influencing regulatory T cell infiltration and epigenetic modifications, modulating the polarization and infiltration of tumor-associated macrophages, and promoting the pro-tumor or anti-tumor properties of natural killer cells and dendritic cells. CD8+ T cells T cells are essential for mediating anti-tumor immunity and T cell-based immunotherapies are indispensable components of cancer therapy. However, the efficacy of T cells in combating cancer can be limited by the suppressive TIME and progressive T cell exhaustion upon chronic antigen exposure [9]. Studies of TFs targeting CD8+ T cells have typically focused on two key aspects. First, TFs that induce CD8+ T cell exhaustion, which is associated with tumor immune escape and tumorigenesis. Second, TFs that enhance the effector functions of CD8+ T cells, thereby supporting their anti-tumor activities. Here, we have summarized several TFs that have recently been shown to participate in these two processes (Fig. 1a). Fig. 1Diagram illustrating the direct-acting transcription factors involved in regulating the physiological and pathological processes of immune cells within the tumor immune microenvironment (TIME). These TFs display either pro-tumor characteristics (red text) or anti-tumor characteristics (blue text) in both innate and adaptive immune cells, including a CD8+ T cells, b regulatory T cells (Tregs), c, d tumor-associated macrophages (TAMs), c natural killer (NK) cells, c dendritic cells (DCs), and d Myeloid-derived suppressor cells (MDSCs). Only TFs summarized in this review are exhibited. Created with BioGDP.com [10] Diagram illustrating the direct-acting transcription factors involved in regulating the physiological and pathological processes of immune cells within the tumor immune microenvironment (TIME). These TFs display either pro-tumor characteristics (red text) or anti-tumor characteristics (blue text) in both innate and adaptive immune cells, including a CD8+ T cells, b regulatory T cells (Tregs), c, d tumor-associated macrophages (TAMs), c natural killer (NK) cells, c dendritic cells (DCs), and d Myeloid-derived suppressor cells (MDSCs). Only TFs summarized in this review are exhibited. Created with BioGDP.com [10] “Exhaustion” refers to a state of effector T cells characterized by low proliferation in response to antigen stimulation, reduced capacity to secrete cytokines, high and sustained expression of multiple inhibitory receptors, and altered transcriptional programming [11, 12]. As T cell exhaustion is primarily driven by persistent antigen/T cell receptor (TCR) stimulation, the TCR-nuclear factor of activated T cell (NFAT) signaling pathway plays a central role in the establishment of CD8+ T cell exhaustion. In addition, the thymocyte selection-associated high-mobility group box protein (TOX) and nuclear receptor 4 A (NR4A) have been identified as key downstream factors in the TCR/NFAT pathway that contribute to CD8+ T cell exhaustion [13–15]. TOX induces a distinct epigenetically programmed state of T cell differentiation, leading to CD8+ T cell exhaustion [13]. NFAT5, which has been previously reported to regulate inflammatory responses in macrophages and the generation of pathogenic CD4+ T helper type 17 cells [16, 17], have been recently demonstrated to be involved in the exhaustion of CD8+ T cells. Tillé et al. have found that NFAT5 binds directly to programmed cell death 1 PD-1 and TOX promoter/enhancer regions of CD8+ T cells. Over-expression of NFAT5 in CD8+ T cells reduces tumor control, while deletion of NFAT5 promotes the accumulation of tumor-specific CD8+ T cells and improves tumor control with decreased expression of exhaustion-associated proteins TOX and PD-1 and high expression of cytokines, such as interferon gamma (IFN-γ) and tumor necrosis factor (TNF). Thus, NFAT5 activation in the TIME enforces CD8+ T cell exhaustion [18]. Interferon regulatory factor 2 (IRF2) has been previously reported to be upregulated in response to IFN-I or IFN-II, which may inhibit interferon gamma receptor (IFNGR) in tumor cells, thereby enhancing tumor-intrinsic resistance to IFN-II [19, 20]. In a recent study, Lukhele et al. have identified IRF2 as a key factor in attenuation and redirection of interferon signaling, thereby programming CD8+ T cell exhaustion to impede tumor control. Rather than acting as an epigenetic regulator that affects chromatin accessibility, IRF2 (independently and/or through TF complexes) interacts with genes enriched in multiple pathways, including IFN signaling, TNF-α/nuclear factor kappa B (NF-κB) signaling, immune exhaustion, and protein translation, ultimately resulting in inhibition of the CD8+ T cell response. In the TIME, IFNs induce and actively sustain increased IRF2 expression in CD8+ T cells, which subsequently establishes a feedback loop to limit IFN signaling. This feedback inhibition transcriptionally programs T cell exhaustion, thereby enabling tumor escape from immune surveillance. Additionally, the authors identified several TFs that are differentially regulated in the absence of IRF2, including NFAT, TOX, NR4A, IRF4, and the basic leucine zipper ATF-like transcription factor (BATF). These TFs directly mediate and counteract T cell exhaustion [21]. T cell factor-1 (TCF-1) is a TF that enhances the effector functions of CD8+ T cells. It is a major T cell developmental TF [22] that also plays a critical role in the regulation of T cell differentiation [23] and preservation of effector function during exhaustion [24]. With the identification of the developmental hierarchy of exhausted T cell (Tex) subsets, studies have elucidated the crucial role of TCF-1 in the development of Tex cells. T cell exhaustion has been classified into a four-stage linear differentiation process, including Texprog1, Texprog2, Texint, and Texterm. During this linear differentiation process, the expression of TCF-1 gradually decreases, whereas that of PD-1 gradually increases [25]. TCF-1 collaborates with several partner TFs, such as B cell lymphoma 6 (BCL6), to regulate T cell exhaustion. Chromatin immunoprecipitation sequencing (ChIP-seq) data reveals that TCF-1 binds to the BCL6 promoter, whereas BCL6 binds to multiple loci of key Texterm cell hallmark genes, transcriptionally repressing the expression of Texterm cell-associated genes [26]. In addition to TCF-1, the gene regulatory network that underlies T cell exhaustion has been systematically studied. Using in vivo single-cell clustered regularly interspaced short palindromic repeats (CRISPR) screens, Zhou et al. have systematically mapped causal gene regulatory networks and identified critical checkpoints for CD8+ cytotoxic T cell differentiation. They have elucidated the functional impacts of three transcription axes (IKAROS-TCF-1, ETS1-BATF, and RBPJ-IRF1). Among them, IKAROS has been identified as a promoter of Tex differentiation by inhibiting TCF-1 and regulating the transition of precursor Tex cells from quiescence to differentiation. ETS proto-oncogene 1 (ETS1) has been found to limit BATF activity through accessible chromatin with high-throughput sequencing (ATAC-seq) analysis of precursor Tex and Tex cells, establishing ETS1 as a gatekeeper for regulating Tex cell differentiation and accumulation. The NOTCH-independent recombination signal binding protein for immunoglobulin kappa J region (RBPJ)–IRF1 axis mediates Tex cell differentiation and is associated with reduced proliferation [27]. However, the molecular mechanisms governing this genetic circuit are yet to be fully elucidated. Follow-up studies are essential and should focus on the functional heterogeneity of intratumoral exhausted T cells. In addition to investigating TFs associated with CD8+ T cell exhaustion, several studies have examined TFs that sustain CD8+ T cell effector functions. T-bet, Eomes, and BATF are well-established context-dependent TFs that play critical roles in promoting CD8⁺ T cell effector functions. Eomes acts in concert with T-bet and serves as a key TF for the full differentiation of effector CD8⁺ T cells. It is induced during effector differentiation and is required for T-bet–independent IFN-γ production [28]. In mouse models with germline deletion of T-bet and T cell–specific deletion of Eomes, these two factors have been identified as essential regulators of adaptive cell-mediated immunity against cancer, promoting CD8⁺ T cell migration into tumor tissue, enhancing IFN-γ production, and suppressing inflammatory IL-17 response [29]. BATF, originally identified as a TF expressed by B cells, supports T cell proliferation and upregulates costimulatory molecules. During the early stages of CD8⁺ T cell differentiation, BATF drives the formation of CD8⁺ terminal effector cells by inducing Sirt1 expression, which enhances ATP synthesis and modulates cellular metabolism to facilitate differentiation [30–32]. IRF4 is predominantly expressed in immune cells and plays a critical role in orchestrating the differentiation of various T cell subsets including T helper (Th) 2, Th9, Th17, and cytotoxic CD8+ T cells [33, 34]. In a recent study, researchers found that IRF4 expression positively correlated with a more differentiated phenotype of CD8+ T cells, and its sustained expression was essential for maintaining CD8+ T cell immunity in a melanoma model [35]. Engineered overexpression of IRF4 in adoptively transferred anti-tumor CD8 + T cells significantly enhances tumor infiltration and facilitates the transition from a naïve/memory-like state to effector T cell states [36]. Therefore, IRF4 serves as a crucial cell-intrinsic driver of T cell infiltration and functions as a transcriptional determinant that is essential for supporting and sustaining the function of anti-tumor CD8+ T cells. Comprehensive descriptions of the molecular characteristics associated with T cell exhaustion and effector T cell function not only provide a framework for deepening our understanding of T cell biology but also facilitate the development of more effective therapeutics to prevent or reverse the exhaustion state. Regulatory T cells (Tregs) Tregs are indispensable for immune homeostasis and serve as critical components that facilitate tumor immune escape [37]. They constitute the primary immunosuppressive immune cell subset in the TIME and are associated with a poor prognosis. Here, we have focused on certain TFs that play a role in regulating Treg functions within the TIME (Fig. 1b). Transcription factor forkhead box protein 3 (FOXP3), which is essential for the development, maintenance, and function of Tregs, predominantly determines Treg identity [38]. However, the mechanism of its action remains unclear, and whether it functions as an activator or repressor, and whether it activates Treg-specific transcription directly or by modulating intermediates, remain debatable. Ramirez et al. have demonstrated that FOXP3 interacts with enhancer-promoter loops in a substantial number of Treg genes through chromatin conformation capture by immunoprecipitation (HiChIP). This supports the direct transactivation function of FOXP3, as single-cell ATAC-seq (scATAC-seq) allows the examination of distinct gene clusters associated with various FOXP3 enhancer-promoter loops in individual Tregs [39]. FOXP3 and its interacting partners assemble into large protein complexes that regulate the transcriptional activity of target genes through activation or repression. Over the past few decades, hundreds of proteins have been identified as FOXP3-interacting partners, such as NFAT, RUNX1, NF-κB, and signal transducer and activator of transcription 5 (STAT5) [40]. In recent years, an increasing number of studies have made significant progress in deciphering the role of the FOXP3 complex in epigenetic remodeling. This complex includes other TFs or epigenetic regulators and modulates histone modifications and DNA methylation patterns to activate or repress target genes [41, 42]. FOXP3 has recently been identified as a transcriptional activator of the C-C motif chemokine receptor 4 (CCR4) and a key regulator of Treg infiltration in the TIME. Specifically, FOXP3 recruits histone acetyl transferase-1 (HAT1) to the distal FOXP3-binding site within the CCR4 promoter. This interaction facilitates the generation of an open euchromatin state by the permissive acetylation of histone-3 lysine residues, leading to higher CCR4 expression in tumor-infiltrating Tregs than in peripheral Tregs in patients with breast cancer. In murine tumor models, genetic ablation of FOXP3 not only reduces CCR4+ Treg infiltration and tumor size but also restores anti-tumor immunity [43]. In contrast, FOXP3 forms a repressive complex by interacting with the TF IKAROS family zinc finger 1 (IKZF1) in Tregs. Ichiyama et al. have demonstrated that IKZF1 associates with FOXP3 to form a complex that includes IKZF3. This complex controls the genomic recruitment of epigenetic activators, thereby inhibiting the expression of target genes such as IFN-γ upon TCR stimulation. The FOXP3-IKZF1-IKZF3 complex competes with epigenetic coactivators, such as p300, for binding to target gene loci through chromatin remodeling. Interference with IKZF1 binding to FOXP3 results in impaired suppressive function and functional instability of Tregs, which can evoke strong anti-tumor immunity [44]. BATF has been identified as a key regulator that influences the epigenetic profiles of Tregs and regulates Treg infiltration in the TIME. BATF is a member of the activator protein-1 (AP-1) family and plays an important role in the effective functioning of CD8+ T cells [45]. Recently, the epigenetic profiles of tumor-infiltrating Tregs have been elucidated. Multi-omics approaches, including ATAC-seq, RNA-seq, scATAC-seq, and scRNA-seq, have been employed to characterize the chromatin accessibility and gene expression of Tregs in the TIME of non-small cell lung cancer (NSCLC). Enhanced BATF expression in Tregs has been identified as a key factor in reprogramming chromatin states by promoting BATF binding to tumor-infiltrating Treg cell-specific chromatin regions, thereby increasing chromatin accessibility at these loci. BATF deficiency in Tregs significantly suppresses tumor growth, whereas elevated BATF expression correlates with poor prognosis [46]. BATF may epigenetically enhance the activation of tumor-infiltrating Tregs. Subsequently, Shan et al. have demonstrated the central role of BATF in regulating activated Tregs, specifically in preventing excessive activation and enhancing their survival, which has been corroborated by findings in a subpopulation of activated Tregs that express multiple tumor necrosis factor receptor (TNFR) genes. TNFR+ Tregs are highly enriched in various types of tumors compared to non-tumor tissues, and are associated with a worse prognosis across solid tumors [47]. As it remains challenging to inhibit suppression by Tregs in cancer therapy without disrupting immune homeostasis, the identification and targeting of TNFR+ Tregs may provide insights into potential immunotherapeutic strategies for treating solid tumors [48]. In addition to epigenetic modifications, other TFs play crucial roles in regulating tumor-infiltrating Tregs. The sex-determining region Y (SRY)-related high-mobility group (HMG) box (SOX) family, which is involved in physiological processes such as cell fate determination and tissue homeostasis [49, 50], plays a critical role in remodeling the TIME by modulating multiple immune cell populations, including effector CD8+ T cells, neutrophils, and B cells [51]. Their crucial role in regulating Treg infiltration into the TIME has been recently identified. Chen et al. have demonstrated that SOX18 overexpression, induced by TGF (transforming growth factor)-β1-pSmad2/3 signaling, promotes the accumulation of immunosuppressive TAMs and Tregs in the TIME via the direct transactivation of CXCL12 and PD-L1 through binding to their promoters. This process intensifies immunosuppression and facilitates hepatocellular carcinoma (HCC) metastasis [52]. Similarly, SOX12 transcriptionally activates the expression of C-C motif chemokine ligand 22 (CCL22) by directly binding to its promoter, which in turn enhances the recruitment and suppressive function of Tregs, thereby contributing to immunosuppression in HCC [53]. Tumor-associated macrophages (TAMs) TAMs constitute one of the most abundant immune cell populations in the TIME and display functional heterogeneity, encompassing both tumor-inhibiting and tumor-promoting phenotypes [54, 55]. TAMs are categorized into two primary phenotypes: classically activated macrophages (M1) and alternatively activated macrophages (M2). The opposing effects of M1 and M2 macrophage subtypes serve as an ideal paradigm for understanding TAM functions within the TIME. However, emerging evidence indicates that some TAMs exhibit both M1 and M2 gene expression patterns or possess transcriptional states that are distinct from those of either subtype. However, this binary classification may be overly simplistic [56]. TFs are closely involved in the dynamic polarization of TAMs, and intricate transcriptional networks have been summarized. Here, we have discussed several newly reported studies on TFs linked to M1, M2, and intermediate phenotypes (Fig. 1c, d). M1 macrophages predominantly express pro-inflammatory and anti-tumor markers such as CXCL9 and STAT1, which are linked to enhanced CD8+ T cell infiltration and activation in tumors [57, 58]. Transcription factor EB (TFEB), which is both inactivated and downregulated in TAMs by breast cancer cell-derived TGFβ1, has been identified as a master regulator of TAMs in breast cancer. TFEB overexpression in macrophages significantly suppresses the growth of orthotopic breast tumors. Mechanistically, TFEB upregulates suppressor of cytokine signaling 3 (SOCS3), thereby inhibiting signal transducer and activator of transcription (STAT3) activation. This subsequently blocks the M2-like polarization of macrophages and reduces Arg1 and IL-10 production [59, 60]. Zinc-fingers and homeoboxes 2 (ZHX2) is a member of the ZHX family that functions as a ubiquitous transcriptional repressor [61]. It has been reported to regulate macrophage polarization by binding to the IRF1 promoter, thereby promoting transcriptional activation of IRF1 in macrophages. In patients with HCC, ZHX2 expression in TAM, which can be downregulated by lactate within the TIME, is correlated with poor survival outcomes [62]. M2 macrophages facilitate tumorigenesis by actively promoting angiogenesis, enhancing migration, and conferring resistance to chemotherapy [58]. STAT6 is a key mediator of the interleukin-4 (IL-4) signaling pathway and plays an essential role in the polarization of M2 TAM. In macrophages with forced STAT6 overexpression, significantly elevated expression levels of M2-associated genes have been observed, whereas ablation of STAT6 abolishes M2 gene expression [63]. STAT6 is a key regulator that drives macrophage M2 polarization by mediating the transcriptional activation of M2-specific genes such as arginase 1 (Arg1), CCL17, and CCL24 [64]. To better elucidate how macrophage polarization is fine-tuned by STAT6, recent studies have emphasized the upstream regulation of STAT6. Yu et al. have demonstrated that TRIM24, a CBP-associated E3 ligase, facilitates STAT6 Lys383 acetylation by ubiquitinating CBP at Lys119. This modification enhances the recruitment of CBP to STAT6. The loss of Trim24 impairs STAT6 acetylation, thereby promoting M2 polarization in both mouse and human macrophages. In a feedback loop, STAT6 reciprocally suppresses TRIM24 expression in M2 macrophages, further reinforcing the establishment of an immunosuppressive tumor niche [65]. Thus, STAT6 acetylation has been identified as a critical negative regulator of macrophage M2 polarization. The ubiquitination of STAT6 at the K450 site is regulated by the E3 ubiquitin ligase TNFR-associated factor 3 (TRAF3). TRAF3 has been found to regulate M2 macrophage programming by ubiquitinating IL-4 response proteins in mice, which positively correlates with the transcriptional activity of STAT6. Moreover, TRAF3 deficiency suppresses tumor growth and lung metastasis in vivo [66]. M2 macrophages constitute a more heterogeneous population than M1 macrophages [67]. They are broadly classified into four subtypes, including M2a, M2b, M2c, and M2d, which can be distinguished by their unique metabolic signatures [68]. Recently, the functions of TFs in regulating specific M2 macrophages have been extensively studied. For instance, STAT3 has been reported to undergo nuclear translocation and induce a pro-tumorigenic macrophage phenotype, with its activation being closely associated with TAMs on the M2 spectrum [69]. A recent study demonstrated that STAT3 activation via Tyr705 phosphorylation is impaired in extracellular signal regulated kinase 5 (ERK5)-deficient TAMs. Furthermore, the blockade of STAT3 suppresses the upregulation of specific M2 markers, indicating that STAT3 plays a pivotal role in the polarization and activation of M2d macrophages [70]. TAMs frequently exhibit mixed or intermediate phenotypes in vivo, simultaneously expressing both anti-tumor and pro-tumor gene signatures, owing to conflicting TIME signals. Single-cell sequencing has revealed a richer diversity of TAM subtypes, indicating that macrophages with varied phenotypes and functions coexist within the tumor landscape [71]. Furthermore, TAM polarization is a highly dynamic and plastic process; M2 macrophages can be repolarized into the M1 state and M1 macrophages can be reprogrammed to express various M2-associated genes [72]. However, the precise molecular mechanisms underlying this phenotypic switch remain unclear. In addition to macrophage polarization, a growing body of evidence demonstrates that increased TAM infiltration and presence within tumor tissues is often correlated with early recurrence and poorer survival in patients. These processes can also be regulated by TFs such as the SOX family [73]. SOX18 overexpression promotes the infiltration of TAMs and Tregs while diminishing cytotoxic T cells, thereby facilitating HCC progression and metastasis in murine models [52]. In clear cell renal cell carcinoma (ccRCC) specimens, intratumoral SOX17 expression negatively correlates with TAM infiltration. ccRCC cells with reduced SOX17 expression activate TAMs by promoting YAP/TEAD1 (yes-associated protein / TEA domain transcription factor 1) signaling, which in turn promotes CCL5 transcription and expression. Subsequently, TAMs reciprocally inhibit SOX17 expression and enhance ccRCC progression via the CCL5/CCR5/STAT3 axis. This interaction establishes a positive regulatory feedback loop involving SOX17, YAP, TEAD1, CCL5, CCR5, and STAT3, thereby modulating the complex interplay between ccRCC and TAMs [74]. The binary M1 and M2 model of TAMs is increasingly viewed as an oversimplification in modern tumor immunology. Consequently, it is necessary to gain a deeper understanding of the molecular regulatory mechanisms governing TAM polarization and infiltration, particularly for TAMs comprising multiple subsets with diverse functions and phenotypes. Natural Killer (NK) cells NK cells are cytotoxic innate lymphocytes that play an essential role in the host’s primary tumor immunosurveillance mechanisms by recognizing antigens without prior sensitization. NK cells efficiently recognize and eliminate transformed cells by releasing cytokines, such as IFN-γ and TNF-α, as well as cytotoxic proteins, including perforin and granzymes [75, 76]. Tumor antigens released from tumor cells killed by NK cells can then be captured by dendritic cells for presentation to CD8+ T cells [77]. NK cells serve not only as potent anti-tumor effector lymphocytes but also play a crucial role in supporting and modulating adaptive anti-tumor immunity. The maturation and functional competence of NK cells is a tightly regulated process that depends on the coordinated actions of a series of TFs [78], such as ID2 inhibitor of DNA binding 2 (ID2) [79], TOX2 [80], and nuclear factor, interleukin 3 regulated (NFIL3) [81]. In recent years, several novel TFs have been found to play crucial roles in regulating NK cell maturation and infiltration (Fig. 1c). For example, in addition to its role in TAMs, ZHX2 has been identified as a crucial regulator of NK cell maturation. ZHX2 overexpression reduces the expression levels of functional molecules, including IFN-γ, TNF-α, granzyme, and perdorin, while interference with ZHX2 expression enhances their expression. ZHX2 directly binds to the zinc finger E-box binding homeobox 2 (ZEB2) promoter and regulates its transcription. ZEB2 is indispensable for the survival of mature NK cells; however, when repressed by ZHX2, it inhibits NK cell maturation, survival, and effector functions [82, 83]. In addition to regulating NK cell maturation, TFs influence NK cell infiltration in the TIME. The ETS transcription factor ELK3, recognized as an oncogene in various cancers, normally represses CXCL16 expression; thus, CXCL16 is significantly upregulated when ELK3 is suppressed [84, 85]. CXCL16 is a chemokine that promotes NK cell recruitment to target tumor cells, both in vitro and in vivo. In triple-negative breast cancer (TNBC), CXCL16-induced NK cell infiltration is critical for enhancing NK cell cytotoxicity [86]. In contrast, TFs affect NK cells by influencing cytokine release. By employing single-cell RNA sequencing, Ni et al. have delineated the transcriptional landscape of mouse tumor-infiltrating NK cells and demonstrated that the hypoxia inducible factor 1 subunit alpha (HIF-1α) suppresses IL-18-driven NF-κB signaling, thereby attenuating the anti-tumor activity of tumor-infiltrating NK cells. Low HIF-1α expression has been significantly associated with high IFN-γ expression in tumor-infiltrating NK cells [87]. NK cells express inhibitory receptors that recognize major histocompatibility complex class-I (MHC-I) molecules [88]. Thus, NK cells complement T cell functions in tumor immunity by targeting tumors that downregulate MHC-I expression and escape CD8+ T cell-mediated clearance [89]. However, within the TIME, NK cells have been reported to exhibit a dysfunctional state reminiscent of exhausted T cells, characterized by impaired effector function and phenotypic alterations. Upon encountering target cells that express activating ligands, but lack MHC-I, NK cells become highly activated. With persistent stimulation, NK cell overactivation leads to their desensitization, thereby abolishing further interactions with cancer cells and resulting in an “exhausted” NK cell state [90]. Moreover, some NK cells exist intrinsically in a functionally impaired state, termed “anergic cells” [91]. These nonresponsive NK cells fail to engage inhibitory receptors during development because of either a lack of inhibitory receptor expression in NK cells or an interaction with MHC-I molecules [92, 93]. To distinguish between anergy and exhaustion conditions of NK cells, Sabag et al. have recently characterized the “anergic” phenotype and have demonstrated functional, transcriptional, and phenotypic similarities to the “exhausted” state in tumor-infiltrating NK cells. They have also identified the zinc-finger TF, early growth response 2 (EGR2), as a common negative regulator of NK cell dysfunction. They have developed an in vivo model of NK cell exhaustion demonstrating that EGR2 gene silencing enhances the ability of NK cells to effectively control tumor growth, augment effector functions, and improve tumor lysis and clearance through the EGR2- diacylglycerol kinase alpha (DGKα) - mitogen-activated protein kinase (MAPK) - extracellular signal-regulated kinase (pERK) signaling axis. Based on RNA sequencing analysis and in vivo models, EGR2 has been found to collaborate with other TFs such as NFAT2 and TOX2. This finding underscores the complexity of transcriptional programs associated with dysfunctional NK cells. They have suggested that targeting EGR2 holds significant promise for enhancing NK-based adoptive therapies. EGR2 inhibition represents a compelling next-generation strategy for overcoming the fundamental limitations of NK cell therapies and their susceptibility to functional exhaustion. By integrating EGR2 modulation into the manufacturing process or combining adoptive transfer with in vivo EGR2-targeting nanoparticles, it is possible to create more resilient, persistent, and potent NK cell products. This approach has the potential to significantly improve the clinical outcomes of adoptive NK cell therapy for solid tumors and hematological malignancies [94]. Further studies focusing on the regulation of NK cell anergy and exhaustion, particularly the TFs involved in the establishment or reprogramming of different states, may provide deeper insights into the molecular mechanisms underlying NK cell dysfunction. Dendritic cells (DC) DCs serve as critical links between innate and adaptive immunity [95] and can integrate a diverse array of incoming signals, effectively orchestrating immune responses. Upon appropriate stimulation, DCs may be induced to mature further and migrate to secondary lymphoid tissues, where they present antigens to T cells, thereby initiating an immune response. The ability of DCs to initiate immune responses or induce tolerance is strictly dependent on their maturation state and the DC subset present [96]. Tumor-infiltrating DCs generally display impaired antigen-presenting capacity and suppress T cell activation and proliferation [97]. Recently, several TFs that play crucial roles in the differentiation and maturation of DCs have been identified (Fig. 1c). DC maturation is enhanced through the upregulation of cytokine expression mediated by TFs, such as NF-κB and SOX9. Park et al. have uncovered a novel necroptosis-mediated transcriptional regulatory circuit that elucidates the upstream mechanisms controlling NF-κB and SOX9 activity. They have demonstrated that receptor interacting serine/threonine kinase 3 (RIPK3) activation phosphorylates tripartite motif containing 28 (TRIM28) at serine 473, resulting in a significant reduction in TRIM28 binding to chromatin. This reduction enhances SOX9 TF activity and promotes the transactivation of NF-κB, thereby increasing cytokine expression and potentiating DC maturation [98]. TFEB is actively expressed in macrophages and plays a pivotal role in macrophage polarization with anti-tumor functions [59], indicating its importance as a key regulator of the differential presentation of exogenous antigens by DCs [99]. Ding et al. have reported that TFEB expression is significantly upregulated in tumor-educated DCs induced by cancer cell supernatants. Suppression of TFEB expression facilitates the differentiation of tumor-educated DCs into more mature DCs, enhancing induction of the CD4+IFN-γ+ T-cell immune responses and suppressing tumor growth in a mouse cancer model [100]. Therefore, TFEB has been associated with pro-tumor properties in DCs, but exhibits anti-tumor characteristics in TAMs, a topic that is further discussed in the following section. Another crucial TF that significantly contributes to the maturation of DCs is CCAAT/Enhancer binding proteins beta (C/EBPβ), which has been shown to play a role in establishing an immunosuppressive tumor microenvironment [101]. The regulated expression of functional C/EBPβ isoforms facilitates the controlled maturation of DCs. In contrast, the presence of lymphoma cells results in the upregulation of C/EBPβ in DCs driving their transformation into an immature and pro-tumorigenic subtype [102]. Distinct isoforms of C/EBPβ have been characterized, exhibiting opposing effects. These isoforms are discussed in detail in subsequent sections of this review. Myeloid-derived suppressor cells (MDSCs) Myeloid-derived suppressor cells (MDSCs), serving as primary drivers of immunosuppression within the TIME, represent a highly heterogeneous population of pathologically activated myeloid cells. In humans, MDSCs are primarily classified into two major distinct subsets: granulocytic/polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (M-MDSCs) [103]. These cells are characterized by their potent ability to suppress the anti-tumor responses of CD8+ T cells, B cells, and NK cells, thereby facilitating tumor immune evasion, progression, and resistance to immunotherapies [104]. The ultimate fate and suppressive capacity of MDSCs are tightly orchestrated by specific TFs (Fig. 1d), which dictate both their developmental trajectories and their suppressive mechanisms. STAT3 is recognized as the master transcriptional regulator of MDSC development and a key driver of the immunosuppressive TIME. While the targeted blockade of STAT3 signaling can decrease the accumulation of MDSCs in the TIME of cancers such as head and neck squamous cell carcinoma [105], its effects are highly subset-specific. Upon STAT3 inhibition, the accumulation of PMN-MDSCs significantly decreases within tumor tissues, whereas the percentage of M-MDSCs remains unaffected or may even increase [106–108]. Furthermore, STAT3 is a crucial regulator of MDSC plasticity, actively controlling the reprogramming of monocytes into M-MDSCs [109, 110] and governing the differentiation of MDSCs into TAMs [111]. Within the hypoxic core of the TIME, HIF-1α emerges as another critical regulator dictating the differentiation and function of MDSCs, often exhibiting complex crosstalk with STAT3. For instance, HIF-1α has been reported to facilitate the differentiation of M-MDSCs into TAMs through a mechanism involving the downregulation of STAT3 activity [112]. Beyond differentiation, recent studies highlight the pivotal roles of both HIF-1α and STAT3 in driving the metabolic reprogramming of MDSCs. Hypoxia-induced HIF-1α accumulation in MDSCs manipulates the transcription of multiple metabolism-related genes, fundamentally altering the energetic profiles of MDSCs [113]. Specific metabolic substrates, such as polyunsaturated fatty acids, mediate MDSC immunosuppressive effects via the Janus kinase (JAK)/STAT3 axis, which regulates the expression of genes related to MDSC expansion, such as S100A8/9, and increases reactive oxygen species production [114]. The activation of TFs and signaling pathways is continuously shaped by the interaction between MDSCs and the complex cellular or metabolic cues within the TIME. These context-dependent signals, in turn, determine the phenotypic and differentiation fate of these cells [115]. Trans-cellular coordinated transcription factors Having characterized the roles of direct-acting TFs in influencing the fate and functional state of individual immune cells, it is crucial to recognize that the TIME is not a collection of isolated entities, but a highly interactive network. Several TFs operate as broadcasters, with one TF in each immune cell driving the secretion of factors that suppress or activate different immune cells. Here, we have referred to them as transcellular coordinate TFs (Table 1). In this section, we have elucidated the regulatory mechanisms of transcellular coordinate TFs in immune-to-immune crosstalk (Fig. 2). Fig. 2Diagram illustrating TFs acting as a bridge to facilitate coordination among diverse immune cells. TAMs inhibit CD8+ T cells infiltration by upregulating ID1, which interacts with STAT1 and suppresses SerpinB2 and CCL4 expression. Deletion of IRF8 in TAMs prevents CD8+ T cell exhaustion. NK cells are essential for optimal anti-tumor CD8+ T cell immune response through the T-bet/Eomes-IFN-γ axis. NK cells also induce MDSC differentiation via the IL-6/STAT3 axis. BATF upregulation prevents CD8+ T cell exhaustion and enhances their effector functions independently of CD4 + T cells. Created with BioGDP.com [10] Diagram illustrating TFs acting as a bridge to facilitate coordination among diverse immune cells. TAMs inhibit CD8+ T cells infiltration by upregulating ID1, which interacts with STAT1 and suppresses SerpinB2 and CCL4 expression. Deletion of IRF8 in TAMs prevents CD8+ T cell exhaustion. NK cells are essential for optimal anti-tumor CD8+ T cell immune response through the T-bet/Eomes-IFN-γ axis. NK cells also induce MDSC differentiation via the IL-6/STAT3 axis. BATF upregulation prevents CD8+ T cell exhaustion and enhances their effector functions independently of CD4 + T cells. Created with BioGDP.com [10] First, the anti-tumor functions of CD8+ T cells, which include their infiltration into the TIME and exhaustion progress, are suppressed through the collaborative actions of TAMs, which are regulated by various TFs. TAMs exhibit high ID1 expression in the TIMEs of patients with colorectal cancer (CRC). ID1 interacts with STAT1, promoting its cytoplasmic distribution and inhibiting its transcriptional regulatory activity on SerpinB2 and CCL4. These effects impede CD8+ T cell infiltration into tumor sites, maintain cancer stemness, and ultimately promote CRC growth and metastasis [116]. Kersten et al. have demonstrated the spatiotemporal co-dependency between TAMs and Tex cells during cancer progression. TAM depletion reduces exhaustion programs in tumor-infiltrating CD8+ T cells, thereby reinvigorating their effector functions in vivo. Additionally, Tex expresses factors that actively recruit monocytes to the TIME and influence their differentiation [117]. In a murine model of breast cancer, Nixon et al. have demonstrated that monocyte-derived TAMs present cancer cell antigens and drive cytotoxic T cell exhaustion, thereby promoting tumor growth in a manner dependent on the TF IRF8. Specific deletion of IRF8 in TAMs prevents CD8+ T cell exhaustion and suppresses tumor progression. However, additional studies are required to identify IRF8-dependent genes that regulate specific aspects of TAM activity as antigen-presenting cells [118]. Second, NK cells not only function as innate effector lymphocytes that directly participate in tumor surveillance but also play a crucial role in facilitating the anti-tumor CD8+ T cell response through the regulation of TFs. Bi et al. have revealed that NK cells are required for an optimal anti-tumor CD8+ T cell immune response via the T-bet/Eomes-IFN-γ axis [119]. Tumor-associated NK cells also play a significant role in MDSC-mediated immune suppression within the TIME, indirectly suppressing cytotoxic T cells. Neo et al. have demonstrated that NK cells acquire a regulatory phenotype during in vitro tumor exposure, inducing MDSC differentiation from both monocytes and neutrophils via the IL-6/STAT3 axis [120]. Third, CD4+ T cells are intricately linked to the effector functions of CD8+ T cells, which are modulated by TFs. Typically, CD8+ T cells rely on IL-21-producing CD4+ T cells to differentiate into functional effector states [121]. However, BATF overexpression may bypass the need for CD4+ T cells to prevent exhaustion and enhance the effector functions of CD8+ T cells [122]. A regulatory network controls immune progression among immune cells within the TIME, and TFs serve as critical bridges in this network. Elucidating the regulatory mechanisms of these TFs may open new avenues for characterizing tumorigenesis. Dual-role transcription factors Both direct-acting and trans-cellular coordinated TFs are assumed to have fixed functional identities. However, there is a third category, dual-role TFs, which is characterized by their capacity to drive entirely opposing immunological outcomes depending on the context. Previous studies have summarized proto-oncogenes that exhibit tumor-suppressive functions, such as KLF4 and IRF4 [123], as well as tumor suppressors that possess oncogenic functions, including Forkhead box O (FOXO) 1/3/4 [124]. In this review, we have focused on TFs that exhibit dual-role functions based on their molecular structures (Table 1, Fig. 3). Depending on the alternative splicing events that generate distinct isoforms or the accumulation of specific post-translational modifications, a single TF can exhibit dramatically opposite effects, from promoting robust anti-tumor immunity to driving severe immunosuppression. The opposing functions of these TFs may be attributed to their isoforms, dimerization states, and the specific target immune cell type. STAT3 serves as the primary mediator of IL-6-type cytokine signaling. In the context of cancer, STAT3 is predominantly characterized as a tumor promoter that facilitates tumor cell proliferation, survival, epithelial-to-mesenchymal transition, resistance to apoptosis, and metastasis. Moreover, the aberrant activation of STAT3 is closely associated with poor prognosis in patients with cancer [125, 126]. Additionally, it is a critical driver of immune evasion. However, under specific conditions, STAT3 can function as a potent tumor suppressor. This heterogeneity partially stems from its different isoforms. There are two alternatively spliced isoforms of STAT3: full-length STAT3α, and C-terminally-truncated STAT3β. Previous studies have demonstrated that these two isoforms exhibit opposing functions during tumor development. STAT3α promotes tumor growth, whereas STAT3β has been identified as a tumor suppressor and prognostic marker in various cancers [127, 128]. In addition, STAT3 has been reported to exhibit distinct effects on various cell types. Specifically, in head and neck squamous cell carcinoma (HNSCC), the application of STAT3 CRISPR to cancer cells, Tregs, and NKs reveals differences in the development of resistance to radiation treatment. STAT3 knockout in Tregs overcomes this resistance, leading to the reprogramming of Tregs and the recruitment and activation of antigen-presenting cells. In contrast, STAT3 knockout in NK cells results in NK cell inactivation and accelerates tumor growth [129]. Since Bickett et al. have not confirmed the exact STAT3 isoform in Tregs or NK cells, it is plausible to hypothesize that distinct STAT3 isoforms play crucial roles in Tregs and NK cells. This hypothesis warrants further investigation in future studies. TFEB plays a dual role in tumor metastasis by regulating both pro-and antimetastatic mechanisms [130]. Similar to STAT3, TFEB exhibits different effects on various types of immune cells within the TIME. In breast cancer, macrophage-specific TFEB knockdown promotes tumor growth by enhancing the tumor-promoting phenotype of TAMs. Simultaneously, TFEB activation inhibits the expression of multiple effector molecules involved in the tumor-promoting function of TAMs, such as Arg1, IL-10, IL-1β, and IL-6 [59]. Therefore, TFEB possesses anti-tumor properties in TAMs. Conversely, its pro-tumor role in DCs has also been established. Knockdown of TFEB in DCs promotes their differentiation into more mature DCs, enhances their immune responses, and suppresses tumor growth in a Lewis lung cancer mouse model, with increased infiltration of CD11c+MHC-II+ DCs and effector T cells into tumor masses [100]. As previously discussed, ZHX2 has been reported to exhibit diverse functions in tumorigenesis by regulating TAM polarization and NK maturation [62, 82]. Thus, ZHX2 is context-dependent, and its function depends on the cell type. In TAMs, low ZHX2 activity promotes a pro-tumor, immunosuppressive environment. Restored or enhanced ZHX2 function in TAMs may reprogram the latter to an anti-tumor state and boost immune response. In NKs, ZHX2 negatively regulates NK cell maturation. Thus, targeting ZHX2 offers a promising strategy for next-generation cancer immunotherapies; however, drug development poses challenges because the therapy requires precision targeting. Fig. 3Diagram illustrating that TFs exhibit dual-role functions because of their isoforms, dimerization states, and the specific target immune cell type. STAT3 has opposing functions in NK cells and Tregs, and also TFEB in DCs and TAMs, and ZHX2 in TAMs and NK cells. Different isoforms of C/EBPβ, including LAP*, LAP, and LIP, exhibit various functions. There are two splicing isoforms of STAT3 that exhibit different functions because of alternative splicing. FOXP3 can form distinct dimerization states: head-to-head dimerization and swap-dimerization, which exhibit different functions. Created with BioGDP.com Diagram illustrating that TFs exhibit dual-role functions because of their isoforms, dimerization states, and the specific target immune cell type. STAT3 has opposing functions in NK cells and Tregs, and also TFEB in DCs and TAMs, and ZHX2 in TAMs and NK cells. Different isoforms of C/EBPβ, including LAP*, LAP, and LIP, exhibit various functions. There are two splicing isoforms of STAT3 that exhibit different functions because of alternative splicing. FOXP3 can form distinct dimerization states: head-to-head dimerization and swap-dimerization, which exhibit different functions. Created with BioGDP.com C/EBPβ is encoded by a single exon but can be translated into three different polypeptides. The longer isoforms, LAP* and LAP, possess an N-terminal transactivation domain that is absent in the short isoform LIP. LIP functions primarily as a repressor of its target genes, while LAP and LAP* activate gene expression [133]. The long LAP/LAP* and the truncated isoform LIP exert opposing effects on DC maturation, likely through the regulation of C/EBPβ target genes involved in differentiation. The balance between LAP/LAP* and LIP isoforms is crucial for determining the kinetics of DC maturation, and C/EBPβ expression is modulated by polarizing factors within the microenvironment [102]. Therefore, it is both necessary and crucial to distinguish the isoforms of C/EBPβ when characterizing its function across various cell types or under different cellular conditions. In addition to the different isoforms, Leng et al. have identified two distinct dimerization states of FOXP3: head-to-head dimerization, which reflects the functional specialization of an ancient DNA-binding domain, and swap-dimerization, which is associated with impaired function [131]. FOXP3 plays acritical role in Treg development and function The distinct dimerization states of FoxP3 influence its ability to determine and maintain Tregs identity by transcriptionally up- or down-regulating hundreds of genes, thereby having divergent implications for Treg function and immune homeostasis [131, 134]. Whether FOXP3 acts as a transcriptional activator, suppressor, or both depending on the target gene, identifying these distinct dimerization states provides a novel framework for understanding FOXP3 functions. In summary, growing evidence has highlighted the intricate interplay between TFs and immune cells within the tumor microenvironment. Further investigations into the regulatory functions of specific isoforms or dimerization states of TFs in distinct immune cell types will undoubtedly provide deeper insights into the molecular mechanisms of TFs and may have profound implications for future cancer therapies. Therapeutic potential and druggability of transcription factors in the TIME Although TFs play foundational roles in regulating immune cells within the TIME, with the exception of nuclear receptors, they have traditionally been considered “undruggable” by small-molecule ligands due to their significant structural disorder and lack of defined small-molecule binding pockets [135, 136]. Furthermore, the highly complex and poorly understood of TF domain function and regulation exacerbates the challenges of targeting these TFs. Recently, significant progress in chemical approaches to ligand discovery and a deeper understanding of TF functions have renewed interest in this filed. Currently, several strategies are being developed to target TFs, most notably the inhibition of TF protein-protein interactions (PPIs), the degradation of TFs via proteolysis-targeting chimeras (PROTACs), and the modulation of TF expression using nucleic acid therapies such as antisense oligonucleotides (ASOs) [136]. TFs commonly require stable PPIs to become transcriptionally active. For example, STAT family of TFs generally require homodimerization or heterodimerization to translocate to the nucleus and activate transcription [137]. STAT dimerization is intrinsically regulated by a Src homology 2 (SH2) domain. TTI-101 is a competitive inhibitor of STAT3 that targets the receptor pY705-peptide binding site within the SH2 domain, thereby blocking its activation and homodimerization. Based on its robust target engagement, favorable safety profile, and clinical benefits observed in preclinical and phase I studies, an ongoing phase II trial is evaluating TTI-101 as a monotherapy and in combination regimens for patients with HCC (NCT05440708) [138, 139]. In its phase I study (NCT03195699), TTI-101 demonstrated antitumor activity in patients with HCC refractory to immune checkpoint inhibitors (ICIs) [140]. Preclinical data corroborate this by showing that TTI-101 increases DC and Th1 infiltration into the TIME in KRAS-mutant lung cancer mouse model, reducing tumor burden [141]. By inducing the selective degradation of TFs via the ubiquitin-proteasome system, PROTACs offer a novel strategy for targeting these proteins [142]. Because PROTACs can induce degradation through weak binding without the need for functional inhibition, they do not require a defined binding pocket at a functional site. This unique mechanism allows them to access traditionally “undruggable” TFs, driving emerging advances in TF-targeted PROTACs development [143]. Notably, some PROTACs have demonstrated significant efficacy even in otherwise refractory tumors, including the STAT3 degraders SD-36 and KT-333. SD-36 is a preclinical small-molecule degrader that potently induces STAT3 degradation in STAT3-driven leukemia and lymphoma models. It exhibits high selectivity over other STAT members and drives complete tumor regression in xenograft mice [144]. Similarly, KT-333 is a potent, highly selective, heterobifunctional small molecule degrader of STAT3. In preclinical studies, once-weekly intravenous administration of KT-333 induced durable tumor regressions in STAT3-dependent T cell lymphomas, and it demonstrated antitumor activity in soild tumors when combined with anti-PD-1 therapy [145]. An ongoing Phase 1a/1b clinical trial (NCT05225584) is currently evaluating the safety, tolerability, and clinical activity of KT-333 in patients with relapsed or refractory lymphomas, large granuclar lymphocytic leukemia, and solid tumors [146]. Importantly, KT_333 treatment induced an IFNγ stimulated gene signature predictive of anti-programmed cell death protein 1 (PD-1) sensitivity, suggesting that it promotes favorable immunodulatory responses within the TIME [146]. As highlighted in previous sections, TF dictate the phenotypes of diverse immune cells in the TIME. TF-driven subsets, particularly Tregs and TAMs, have emerged as highly promising therapeutic candidates. The presence of Tregs remains a complicating factor for the clinical efficacy of immunotherapy [147]. Efforts to therapeutically modulate Tregs have primarily focused on three strategies: depleting tumor-infiltrating Tregs, functionally impairing their suppressive activity, and disrupting the metabolic pathways that support their biological functions. However, broad Treg targeting can disrupt systemic tolerance and drive high-grade immune toxicity [148]. Consequently, emerging studies are attempting to target FOXP3 specifically rather than depleting Treg cells entirely. AZD8701, a FOXP3-ASO designed to selectively reduce human FOXP3 expression and reverse Treg immunosuppressive function, recently completed a phase I clinical Trial (NCT04504669) [149]. Although the clinical development of AZD8701 is currently halted at Phase I due to suboptimal efficacy, it provided crucial proof-of-concept that targeting FOXP3 via nucleic acid therapeutics is clinically safe [150]. In addition to nucleic acids, researchers have used the crystal structure of the FOXP3 homodimer to develop stapled alpha-helical pipetides. By blocking FOXP3 PPIs through molecular mimicry, these peptides impede Treg function and drive in vivo gene expression changes consistent with FOXP3 dysfunction [151]. Furthermore, because the human FOXP3 gene encodes two major isoforms through alternative splicing, morpholino-mediated FOXP3 isoform shifting represents another potentially promising immunotherapeutic approach for cancer treatment [152]. TAMs undergo a dynamic process known as “macrophage polarization”, which balances the M1/M2 ratio and often shapes an immunosuppressive TIME. Numerous studies have reported the significant role TAMs play in establishing this inhibitory environment to mediate resistance to ICIs [153]. Current TAM-targeting strategies include reducing TAM recruitment to the TIME, depleting existing TAMs, repolarizing TAMs towards an M1-like phenotype, and blocking “don’t eat me” signals [154]. Focusing on TFs, STAT3 within the JAK/STAT pathway has been heavily implicated in driving M2 polarization. Consequently, several therapeutic strategies targeting STAT3, currently in preclinical and clinical stages, are garnering attention for their potential to enhance TAM-targeted immunotherapy [155–157]. ICIs have significantly reshaped cancer immunotherapy and have demonstrated transformative effects across various malignancies. However, the limited overall effectiveness of ICIs raises critical questions about the mechanisms driving both primary and acquired resistance. The combination of TF-targeting immunotherpies and ICIs sheds light on a promising new strategy to overcome this. For example, in the phase I trial of TTI-101, a patient treated with atezolizumab and bevacizumab within 30 days of discontinuing TTI-101 demonstrated a renew clinical response after two months. This suggests that TTI-101 may play a role in re-sensitizing tumors to ICI therapy [139]. Preclinical data supports this; in a KRAS-mutant lung cancer mouse model, the combination of anti-PD-1 monoclonal antibody with TTI-101 significantly decreased the number of lung surface tumors compared to either agent alone [158]. Furthermore, in the phase I trial of AZD8701, the drug was combined with durvalumab in 18 patients with advanced solid tumors, yielding a partial response in one patient [150]. Ultimately, integrating TF-targeting approaches with ICIs and traditional chemoradiation may help to optimize combination strategies and improve patient outcomes [159]. Summary and outlook In this review, we have summarized the emerging TFs that regulate immune cells in the tumor microenvironment and updated the upstream regulatory mechanisms of some TFs identified over the past 5 years. Rather than categorizing these TFs by their resident immune cell types, we have classified them based on their operational mechanisms, including direct-acting, trans-cellular coordinated, and dual-roles. The distinct functional modalities of TFs within the TIME should be emphasized to advance the design of highly specific therapeutic interventions. For direct-acting TFs that intrinsically dictate immune cell fate, ex vivo genetic engineering (e.g., CRISPR/Cas9) during adoptive cell therapy provides a robust method to permanently rewire intracellular programming, such as reversing effector cell exhaustion [160]. Furthermore, the pathological effects of transcellular coordinate TFs, which orchestrate the immunosuppressive immune-to-immune crosstalk, can be effectively neutralized by targeted therapies that interrupt these specific intercellular networks [161]. Finally, the therapeutic modulation by dual-role TFs requires precise biochemical approaches that distinguish functionally divergent isoforms, splice variants, and post-translational modifications [162]. Strategies should shift the balance away from pro-tumorigenic TF variants without compromising the structural integrity or anti-tumor functions of the wild-type protein. Ultimately, classifying TFs according to their operational mechanisms provides a critical translational framework for the development of next-generation precision immunotherapies. Undoubtedly, growing evidence has facilitated a deeper understanding of the molecular mechanisms underlying TF-mediated TIME reprogramming. However, certain limitations remain. The regulatory network of TFs in the TIME is a complex process, and the mechanisms underlying their pro-tumorigenic or anti-tumorigenic functions remain incompletely understood. The upstream drivers of TF activity are yet to be identified. Most experiments have been conducted using murine models, which may not fully recapitulate the human tumor microenvironment. Additionally, although the crucial roles of certain TFs in regulating tumor initiation and progression have been well documented, the development of immunotherapeutic strategies targeting TFs remains challenging. Therefore, further investigations are essential to elucidate the molecular mechanisms of TFs in human cancers. The analyses of TFs as an integrated network may have significant implications for tumor research and treatment.